ArticleFrontiers in endocrinology2025
A threshold of β-CTX (0.3 ng/mL) with low estradiol identifies high-risk perimenopausal women for bone loss: a cross-sectional study.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Increasing evidence has demonstrated accelerated bone loss during perimenopause. The detection of bone loss relies heavily on dual-energy X-ray absorptiometry (DXA). However, DXA is not sensitive enough for early bone loss. Therefore, an easy and sensitive method is urgently needed for identifying high-risk women before irreversible bone loss occurs. Objective: To 1) define a clinically meaningful β-CTX threshold (≥ 0.3 ng/mL) for perimenopausal bone loss prediction, 2) assess the predictive value of E2 and β-CTX, both individually and in combination, for bone loss in perimenopausal women. Methods: One hundred and thirty female participants met the inclusion/exclusion criteria were enrolled in this study from March 2024 to March 2025. Enrolled subjects underwent DXA examination and blood tests, including measurements of E2, β-CTX, TP1NP, D3, and IGF-1. The correlations between E2, β-CTX, TP1NP, D3, IGF-1 and T-scores were performed using Spearman correlation analysis. The predicting value of E2, β-CTX and combination for perimenopausal bone loss were studied by ROC curve analysis. Results: There were significant correlations between E2, β-CTX, TP1NP and T-scores, but not between D3, IGF-1 and T-scores. The threshold value of E2 alone in predicting perimenopausal bone loss was 62.7 pmol/L. Its sensitivity and specificity were 79.1% and 93.2%, respectively. The threshold value of β-CTX alone in predicting perimenopausal bone loss was 0.30 ng/mL. Its sensitivity and specificity were 79.3% and 96.4%, respectively. The ROC curve of E2 combined with β-CTX showed that the AUC was 0.950. Its sensitivity and specificity were 88.4% and 97.7%, respectively, which were higher than that in E2 and β-CTX alone. Conclusion: A clinically meaningful β-CTX threshold (≥ 0.3 ng/mL) was defined for perimenopausal bone loss prediction, and the combination of E2 and β-CTX is a simple and reliable method for predicting perimenopausal bone loss, with high sensitivity and specificity. A threshold of β-CTX (0.3 ng/mL) with low estradiol identifies high-risk perimenopausal women for bone loss.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.